The vaccine against COVID-19 from the pharmaceutical company Pfizer has an efficacy of more than 90%, as indicated by its manufacturers on Monday. The first interim results in large-scale trials show that the Pfizer / BioNTech candidate performs much better than most experts expected. Additionally, the company has indicated that no serious side effects have been reported.
“Today is a great day for science and humanity,” said Dr. Albert Bourla, president and CEO of the company in statements to the Guardian. The first set of results from our phase 3 trial of the COVID-19 vaccine offers the first evidence of the ability of our vaccine to prevent COVID-19, “he said.
“We have reached this milestone in our vaccine development program at a time when the world needs it most with infection records reaching new records every day, saturated hospitals and economies struggling to reactivate,” added Bourla.